ME
Jyong Biotech Ltd. Ordinary Shares
MENS · NASDAQ
$2.12 -2.12% (-$0.05)
1M -5.50%
Market Cap $158.1M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$1.82
14.2% downside
Current Price
$2.12
Undervalued Fair Value Overvalued
According to Bulios Fair Price, MENS is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
-
N/A P/E N/A
EV/FFO N/A
EV/EBITDA N/A
Growth
-
N/A EPS growth N/A
Book val. growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
FCF margin N/A
Net margin N/A
Quality
57 /100
Average ROIC 45.99%
Asset turnover 0.00x
ROA 22.48%
Debt
1 /100
High Current ratio 0.45x
Int. coverage -1.03x
Debt/Equity N/A
Stability
15 /100
Unstable Beta 2.24x
Profitable years 0
EPS volatility 54.12%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about MENS
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Fu-Feng Kuo
Employees
27
Headquarters
New Taipei City